Topic

Webcasts

Webinar Date/Time: Thu, Oct 12, 2023 2:00 PM EDT

Driving Patient-First Affordability in Seconds, Not Days: Accelerating Time to Therapy

Leslie Sandberg Orne is the president and chief executive officer of Trinity Life Sciences.

Articles

A phased launch approach may ultimately be more sustainable and enable maximum market penetration and commercial success with less upfront investment than traditional “go-for-broke” strategies.

Strategies for Success in an Evolving Commercialization Landscape 

Meg Rivers is the former managing editor of 

In this exclusive Q&A, Vishali Amin, chief of staff to the office of the president and senior director of customer success for Kalderos, discusses the biggest hurdles to drug affordability, how patients can become aware of drug discounts, how drugs are selected for regulatory discount programs, and drug pricing strategies.

Current Drug Affordability Challenges

Corey Ford is the vice president of reimbursement and policy insights for AmerisourceBergen.

As we approach the one-year anniversary of the IRA being signed into law, questions remain about how the new law will reverberate changes across the biopharma industry. 

AdobeStock_527614812_Inflation Reduction Act is shown using the text and the US flag, By Andrii

What’s Next for Biopharma Under the Inflation Reduction Act

Kevin Hagan, president and CEO of the PAN Foundation, discusses how pharma can help Medicare patients post-IRA reform. 

What Can Pharma Do for Patients Post IRA?

Kevin Hagan, president and CEO of the PAN Foundation, spoke to PharmExec about the recent IRA changes to Medicare and how it positively effects patients. 

Pharma USA 2023: IRA Impact on Patients

Webinar Date/Time: Thu, Mar 16, 2023 11:00 AM EDT



Confronting a Challenging Macroeconomic Environment with Innovation

William Borden is a freelance journalist covering the pharmaceutical industry. He is based in New Jersey.

Curative-type therapies offer great hope in further transforming treatments for cancer and other diseases, but addressing the economics of these products—and ultimately the cost-benefit equation—is daunting. What is being done to smooth the path for pricing and reimbursement?

The Price of Innovation: ‘Paying for a Cure’ Remains Costly Proposition 

Former chief strategy officer, Novartis Pharmaceuticals Corporation

Head of access & BDL strategy, Novartis Pharmaceuticals Corporation

Principal, Leavitt Partners, an HMA Company

Director, Leavitt Partners, an HMA Company

Value-based price for access (VBPA) may increase access of specialty drugs for patients.

Payers Believe Lowering Drug Prices While Improving Patient Access Is Possible—but There’s a Catch

Ford discusses how rising drug costs in impact patients, and how they can either avoid them or find less-expensive options.

Pricing